E. Bain

发表

Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects

Dennis S. Charney, Allison C. Nugent, Suzanne Wood, 2005, Biological Psychiatry.

Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls.

Peter Herscovitch, Alexander Neumeister, W. Drevets, 2004, Archives of general psychiatry.

Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder.

Luke Clark, Dara M Cannon, B. Sahakian, 2005, The American journal of psychiatry.

Defining EGFR amplification status for clinical trial inclusion

M. J. van den Bent, M. Weller, T. Gorlia, 2019, Neuro-oncology.

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD

J. McGough, T. Garimella, W. Abi-Saab, 2011, Neuropsychopharmacology.

Relationship between serotonin-1A binding and HPA axis in subjects with major depression and healthy controls

D. Luckenbaugh, A. Nugent, W. Drevets, 2008, NeuroImage.

Alterations in neural correlates of autonomic control in females with major depressive disorder

W. Drevets, J. Thayer, A. Nugent, 2008 .

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand

M. J. van den Bent, T. Gorlia, P. Ansell, 2019, Neuro-oncology advances.

ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

K. Aldape, W. Curran, M. Gilbert, 2019, Neuro-Oncology.

Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression

W. Drevets, A. Nugent, D. Charney, 2013, European Neuropsychopharmacology.

D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET.

G. Marek, M. Day, G. Fox, 2010, The international journal of neuropsychopharmacology.

Habenula Volume in Bipolar Disorder and Major Depressive Disorder: A High-Resolution Magnetic Resonance Imaging Study

J. Roiser, W. Drevets, Sean Marrett, 2011, Biological Psychiatry.

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

A. Othman, W. Robieson, E. Bain, 2016, The American journal of psychiatry.

New directions in the treatment of anxiety disorders

E. Bain, P. Candilis, 2000 .

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

T. Mikkelsen, M. J. van den Bent, A. Scott, 2018, Neuro-oncology.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Hao Xiong, Helen Wheeler, John Simes, 2017, Cancer Chemotherapy and Pharmacology.

Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry

Michael P. Milham, Linda M. Laird, Allison C. Nugent, 2006, NeuroImage.

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

C. Chuang-Stein, L. Shafner, A. Othman, 2017, JMIR mHealth and uHealth.

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

W. Curran, M. Gilbert, M. Macsai, 2022, Neuro-oncology.

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).

T. Mikkelsen, N. Butowski, M. Bent, 2016 .

A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression.

B. Sahakian, W. Drevets, D. Luckenbaugh, 2008, Bipolar disorders.

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

K. Aldape, W. Curran, M. Mehta, 2019, Journal of Neuro-Oncology.

An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti‐EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR

H. Xiong, E. Bain, R. Menon, 2019, Journal of clinical pharmacology.

A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

A. Othman, W. Robieson, R. Lenz, 2014, Schizophrenia bulletin.

Normal Prefrontal Gamma-Aminobutyric Acid Levels in Remitted Depressed Subjects Determined by Proton Magnetic Resonance Spectroscopy

Gregor Hasler, Dennis S. Charney, Alexander Neumeister, 2005, Biological Psychiatry.

Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication

Dennis S. Charney, Allison C. Nugent, Carlos A. Zarate, 2010, NeuroImage.

Sex differences in the neural correlates of autonomic arousal: a pilot PET study.

Julian F Thayer, W. Drevets, J. Thayer, 2011, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

Reduced Serotonin Type 1A Receptor Binding in Panic Disorder

Peter Herscovitch, Richard E. Carson, Dennis S. Charney, 2004, The Journal of Neuroscience.

Reduced posterior hippocampal volume in posttraumatic stress disorder.

Suzanne Wood, Alexander Neumeister, Meena Vythilingam, 2008, The Journal of clinical psychiatry.

Mitigating the Effects of Nonadherence in Clinical Trials

Earle E. Bain, P. Skolnick, T. Shiovitz, 2016, Journal of clinical pharmacology.

Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression

W. Drevets, A. Nugent, C. Zarate, 2013, Journal of psychopharmacology.

ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)

W. Curran, M. Mehta, P. Canoll, 2017 .

A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.

D. L. McNeill, W. Abi-Saab, M. Saltarelli, 2012, The Journal of clinical psychiatry.

No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder.

W. Drevets, D. Luckenbaugh, A. Nugent, 2005, The American journal of psychiatry.

HG-44EVALUATION OF ABT-414 IN CHILDREN WITH HIGH GRADE GLIOMA (HGG) AND DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Peter Ansell, Darren Hargrave, Birgit Geoerger, 2016 .

Heart rate variability during motor and cognitive tasks in females with major depressive disorder

W. Drevets, J. Thayer, A. Nugent, 2011, Psychiatry Research: Neuroimaging.

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.

A. Othman, E. Bain, G. Haig, 2017, The Journal of clinical psychiatry.

327OEpidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma

M. Bent, A. Lassman, P. Ansell, 2017 .

Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial

T. Mikkelsen, N. Butowski, M. Bent, 2017 .

ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA

M. Bent, A. Lassman, P. Ansell, 2017 .

Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication

J. Price, W. Drevets, Sean Marrett, 2010, NeuroImage.